On April 10, 2024, the Centers for Medicare & Medicaid Services (CMS) issued the fiscal year (FY) 2025 Medicare hospital inpatient prospective payment system (IPPS) and long-term care hospital prospective...
BluePath’s initial acquisition expands its product and service offerings in the biopharmaceutical commercialization services sector. BluePath Solutions, a Los Angeles based health economics and value communication consulting firm announced today that...
In a recently published microcosting analysis using trial healthcare resource utilization data, our colleagues estimated post-infusion costs with the chimeric antigen receptor (CAR) T cell therapy, idecabtagene vicleucel (ide-cel),...
Allogeneic hematopoietic cell transplantation (allo-HCT) has the potential for curative outcomes in a variety of hematologic malignancies but are often associated with adverse events, specifically chronic graft versus host disease...
Our colleagues recently participated in one of the first large-scale claims analyses to date on estimating the time to diagnosis across a range of cancer types. The recent article, published...
Our colleagues recently participated in the first systematic literature review and meta-analysis on the signs and symptoms associated with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). The recent open access...
With the marketplace flush with Chimeric antigen receptor (CAR) T-cell therapies to treat relapsed/refractory large B-cell lymphoma (LBCL), one of the key clinical and economic differentiators may be the risk...
A recent publication by our colleagues uses real world data to demonstrate the real world effectiveness of a recently approved therapy while maintaining safe outcomes. Extended-release calcifediol (ERC), active vitamin...
Our colleagues recently published a large-scale analysis to comprehensively assess breast, colorectal, cervical, lung, and prostate cancer screening rates and trends in the US over time among individuals for whom...
Payers who offer Medicare Part D plans may receive additional compensation after the point-of-sale. These funds are known as Direct & Indirect Remuneration (DIR), and account for growing levels of...
